Candel Therapeutics Inc (NASDAQ: CADL) is -4.95% lower on its value in year-to-date trading and has touched a low of $1.40 and a high of $14.60 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CADL stock was last observed hovering at around $8.90 in the last trading session, with the day’s loss setting it -0.65%.
Currently trading at $8.25, the stock is -4.54% and 0.04% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.08 million and changing -7.30% at the moment leaves the stock 22.57% off its SMA200. CADL registered 489.29% gain for a year compared to 6-month gain of 17.44%. The firm has a 50-day simple moving average (SMA 50) of $8.2469 and a 200-day simple moving average (SMA200) of $6.730975.
The stock witnessed a -21.20% loss in the last 1 month and extending the period to 3 months gives it a 34.04%, and is 3.90% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.31% over the week and 10.97% over the month.
Candel Therapeutics Inc (CADL) has around 38 employees, a market worth around $389.69M and $0.00M in sales. Distance from 52-week low is 489.29% and -43.49% from its 52-week high. The company has generated returns on investments over the last 12 months (-79.58%).
The EPS is expected to grow by 29.34% this year, but quarterly earnings will post 0.00% year-over-year.
97.0 institutions hold shares in Candel Therapeutics Inc (CADL), with institutional investors hold 54.17% of the company’s shares. The shares outstanding are 46.93M, and float is at 34.49M with Short Float at 9.67%. Institutions hold 44.13% of the Float.
The top institutional shareholder in the company is NORTHPOND VENTURES, LLC with over 1.94 million shares valued at $12.0 million. The investor’s holdings represent 6.477 of the CADL Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 0.82 million shares valued at $5.1 million to account for 2.819 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 0.82 million shares representing 2.8035 and valued at over $5.08 million, while STATE STREET CORP holds 1.5824 of the shares totaling 0.47 million with a market value of $2.93 million.
Candel Therapeutics Inc (CADL) Insider Activity
The most recent transaction is an insider sale by Nichols William Garrett, the company’s Chief Medical Officer. SEC filings show that Nichols William Garrett sold 45,316 shares of the company’s common stock on Mar 18 ’25 at a price of $8.76 per share for a total of $0.4 million. Following the sale, the insider now owns 52493.0 shares.
Candel Therapeutics Inc disclosed in a document filed with the SEC on Mar 18 ’25 that Barone Francesca (Chief Scientific Officer) sold a total of 32,146 shares of the company’s common stock. The trade occurred on Mar 18 ’25 and was made at $8.76 per share for $0.28 million. Following the transaction, the insider now directly holds 96527.0 shares of the CADL stock.
Still, SEC filings show that on Mar 18 ’25, Tak Paul Peter (Chief Executive Officer) disposed off 25,772 shares at an average price of $8.77 for $0.23 million. The insider now directly holds 226,140 shares of Candel Therapeutics Inc (CADL).
